National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA; Commissioned Corps, US Public Health Service, Rockville, MD.
National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA.
J Pediatr. 2018 Feb;193:164-171. doi: 10.1016/j.jpeds.2017.09.057. Epub 2017 Dec 14.
To quantify vaccinations administered outside minimum and maximum recommended ages and to determine attendant costs of revaccination by analyzing immunization information system (IIS) records.
We analyzed deidentified records of doses administered during 2014 to persons aged <18 years within 6 IIS sentinel sites (10% of the US population). We quantified doses administered outside of recommended ages according to the Advisory Committee on Immunization Practices childhood immunization schedule and prescribing information in package inserts, and calculated revaccination costs. To minimize misreporting bias, we analyzed publicly funded doses for which reported lot numbers and vaccine types were consistent.
Among 3 394 047 doses with maximum age recommendations, 9755 (0.3%) were given after the maximum age. One type of maximum age violation required revaccination: 1344 (0.7%) of 194 934 doses of the 0.25-mL prefilled syringe formulation of quadrivalent inactivated influenza vaccine (Fluzone Quadrivalent, Sanofi Pasteur, Swiftwater, PA) were administered at age ≥36 months (revaccination cost, $111 964). We identified a total of 7 529 165 childhood, adolescent, and lifespan doses with minimum age recommendations, 9542 of which (0.1%) were administered before the minimum age. The most common among these violations were quadrivalent injectable influenza vaccines (3835, or 0.7% of 526 110 doses administered before age 36 months) and Kinrix (GlaxoSmithKline Biologicals, Rixensart, Belgium; DTaP-IPV) (2509, or 1.2% of 208 218 doses administered before age 48 months). The cost of revaccination for minimum age violations (where recommended) was $179 179.
Administration of vaccines outside recommended minimum and maximum ages is rare, reflecting a general adherence to recommendations. Error rates were higher for several vaccines, some requiring revaccination. Vaccine schedule complexity and confusion among similar products might contribute to errors. Minimization of errors reduces wastage, excess cost, and inconvenience for parents and patients.
通过分析免疫信息系统(IIS)记录,量化超出最小和最大建议年龄范围接种的疫苗数量,并确定重新接种的相关成本。
我们分析了 2014 年在 6 个 IIS 监测点(占美国人口的 10%)内年龄<18 岁人群接种的、经鉴定的、不记名疫苗剂量记录。我们根据免疫实践咨询委员会(Advisory Committee on Immunization Practices)儿童免疫计划时间表和包装说明书中的处方信息,量化了超出推荐年龄的疫苗剂量,并计算了重新接种的成本。为了尽量减少错误报告偏倚,我们分析了公共资助的疫苗剂量,这些剂量的报告批号和疫苗类型一致。
在有最大年龄建议的 3394047 剂疫苗中,有 9755 剂(0.3%)在最大年龄之后接种。有一种最大年龄违规需要重新接种:194934 剂 0.25 毫升预充式四价流感疫苗(Fluzone Quadrivalent,Sanofi Pasteur,Swiftwater,PA)中有 1344 剂(0.7%)在年龄≥36 个月时接种(重新接种成本为 111964 美元)。我们共发现 7529165 剂儿童、青少年和终身剂量有最小年龄建议,其中 9542 剂(0.1%)在最小年龄之前接种。这些违规中最常见的是四价流感疫苗(3835 剂,占 526110 剂在 36 个月前接种的疫苗的 0.7%)和 Kinrix(GlaxoSmithKline Biologicals,Rixensart,比利时;DTaP-IPV)(2509 剂,占 208218 剂在 48 个月前接种的疫苗的 1.2%)。最小年龄违规(推荐时)的重新接种成本为 179179 美元。
在推荐的最小和最大年龄之外接种疫苗的情况很少见,这反映了对建议的普遍遵守。几种疫苗的错误率更高,其中一些需要重新接种。疫苗计划的复杂性和类似产品之间的混淆可能导致错误。减少错误可以降低浪费、额外成本和家长及患者的不便。